The non-competitive NMDA receptor antagonist MK-801 elicits a behavioural syndrome in rodents characterized by hyperlocomotion and stereotypies, which is antagonized by antipsychotic drugs. NMDA receptor antagonists increase prefrontal cortex (PFC) activity in rodents, as assessed by electrophysiological and neurochemical measures. The increase in glutamate outflow induced by systemic MK-801 administration in the medial PFC (mPFC) is prevented by the local administration of clozapine (Clz). In the present study, we examine whether a PFC lesion alters the behavioural syndrome induced by MK-801 in rats and the Clz-induced antagonism of MK-801 actions. We evaluated the hyperlocomotion, stereotypies and other behavioural changes induced by MK-801 in the open field and the effect of electrolytic lesions of the mPFC, and of cortical transection on the behavioural syndrome induced by MK-801 and its reversal by Clz. MK-801 (0.1-0.2 mg/kg i.p.) reduced rearings but only the higher dose induced hyperlocomotion. At this dose, MK-801 also increased disorganized movements, head weavings, and induced ataxia signs. An electrolytic lesion of the mPFC markedly reduced the number of rearings pre-treatment but caused a very slight attenuation of MK-801-induced hyperlocomotion. Cortical transection did not significantly alter MK-801 effects. Clz administration (1 mg/kg s.c.) significantly attenuated hyperlocomotion, head weavings and ataxia signs induced by MK-801 but did not prevent the decrease in rearings. The effect of Clz was essentially unaffected by electrolytic lesions of the mPFC. These results show that MK-801-induced motor syndrome and its reversal by Clz are mostly independent on PFC integrity.
Introduction
Non-competitive NMDA receptor antagonists, such as phencyclidine or MK-801 induce a potent behavioural syndrome (hyperactivity, ataxia signs, stereotypies), as well as cognitive and sensory deficits in experimental animals that resemble human schizophrenia symptoms (Javitt and Zukin, 1991 ; Krystal et al., 1994 ; Malhotra et al., 1997 ; Newcomer et al., 1999) . NMDA receptor antagonists also aggravate this array of symptoms in schizophrenia patients (Krystal et al., 2003) . In common with schizophrenia symptoms, the behavioural effects of NMDA receptor antagonists are sensitive to treatment with antipsychotic drugs (Geyer et al., 2001 ; Krystal et al., 2003) .
Despite the widespread use of NMDA receptor antagonists as pharmacological models of schizophrenia, their neurobiological basis of action is still poorly understood. Neuroimaging studies indicate that a sub-anaesthetic dose of ketamine increases the activity of the prefrontal cortex (PFC) in human volunteers . In experimental animals, NMDA receptor antagonists such as MK-801 or phencyclidine have been shown to increase the neuronal activity in the medial prefrontal cortex (mPFC) (Jackson et al., 2004 ; Kargieman et al., 2007 ; Suzuki et al., 2002) and glutamate release in this area (Adams and Moghaddam, 2001 ; Ló pez-Gil et al., 2007 ; Lorrain et al., 2003 ; Moghaddam et al., 1997) . These drugs also increase the release of monoamines in the mPFC, such as dopamine (Mathé et al., 1999 ; Moghaddam and Adams, 1998 ; Schmidt and Fadayel, 1996) , serotonin (Adams and Moghaddam, 2001 ; Amargó s-Bosch et al., 2006 ; Ló pez-Gil et al., 2007 ; Martin et al., 1998 ; Millan et al., 1999) and acetylcholine (Nelson et al., 2002) . Given the prominent role of monoamines in PFC function (Robbins, 2000) these changes might partly mediate MK-801-or phencyclidine-induced behaviours.
The PFC is involved in a large number of higher brain functions such as working memory, action planning and behavioural inhibition (Fuster, 1997 ; Miller and Cohen, 2001) , which are altered in schizophrenia patients. Macroscopic and microscopic pathological changes have been reported in the PFC of schizophrenia patients, e.g. reduction layer thickness, increased packing density of pyramidal neurons and reduced number and function of chandelier GABAergic neurons (Harrison, 1999 ; Lewis et al., 2005) . The PFC exerts a top-down control of many other cortical and subcortical areas in the brain including motor and limbic areas with which the PFC is reciprocally connected in most instances (Miller and Cohen, 2001) . Pyramidal neurons in the PFC receive a large array of inputs from sensory and associative cortical areas, as well as from the thalamus, the hippocampus and other subcortical structures. In turn, axons of pyramidal neurons project to and modulate neuronal activity in these areas (Fuster, 1997 ; Groenewegen and Uylings, 2000 ; Miller and Cohen, 2001) . Since NMDA receptor antagonists increase the activity of PFC neurons (Homayoun and Moghaddam, 2007a ; Jackson et al., 2004 ; Kargieman et al., 2007 ; Suzuki et al., 2002) , it may be possible that the behavioural syndrome evoked by these agents results from a PFC-induced activation of cortical and subcortical motor areas secondary to the increase of PFC activity. In the present study we further characterized the behavioural syndrome produced by MK-801 and examined whether a lesion of the mPFC can prevent or attenuate some of the behavioural signs induced by MK-801. Moreover, we also examined whether the clozapine (Clz) reversal of MK-801 effects depends on mPFC integrity.
Methods

Animals
Male Wistar rats (250-300 g) were obtained from IIBCE Bioterio (Montevideo, Uruguay). All rats were maintained in groups of six in clear plastic cages (50r30r20 cm) at 22¡2 xC on a constant lightdark cycle (07 : 00-19 : 00 hours) and had unlimited access to food and water. Animal care followed the European Union regulations (O.J. of E.C. L358/1 18/12/1986) and experiments were conducted according to local ethical guidelines (IIBCE, Montevideo, Uruguay).
Drugs and treatments
]cyclohepten-5,10-imine hydrogen maleate)] was from Sigma RBI (Natick, MA, USA), Clz was from Tocris (Bristol, UK) and ketamine (50 mg/ml) and xylazine (20 mg/ml) were from Konsol Kö ning SA Laboratory (BA, Argentina). MK-801 was dissolved in saline and Clz was dissolved in a minimal volume of 0.1 M HCl, and diluted with saline (pH adjusted to 5-6 with NaOH). Aliquots were prepared and stored at x20 xC. Clz vehicle was also stored at x20 xC.
Drugs were injected intraperitoneally (i.p.) or subcutaneously (s.c.) and control groups received the corresponding saline or vehicle injection. MK-801 was injected i.p. at 0.1 and 0.2 mg/kg, Clz was injected at 1 mg/kg s.c. In experiments involving a single drug injection, drugs were administered 30 min before starting the behavioural testing. In experiments assessing the Clz reversal of MK-801 actions, the antipsychotic was administered 5 min before MK-801 (see Figure 1 ). Drugs were administered at 1 ml/kg. All experiments were performed between 08 : 00 and 13 : 00 hours.
Behavioural experiments
Rats were brought in their home cages to the experimental room, identified and weighed 1 d before the behavioural experiments to allow acclimation to the test environment. The experimental room was under controlled temperature (22¡2 xC) and the behavioural testing was conducted using the open-field (OF) paradigm, as previously described (Lagos et al., 1998 ; Scorza et al., 1996) . The same OF was used in all experiments. Briefly, the OF apparatus consists of a square Plexiglas cage (60r60r40 cm) with red walls to minimize outside light and noise. The OF is equipped with an optical system to measure animal activity, consisting of eight photocell beams on each side of the arena, forming a grid of 64 equally sized squares. The OF is connected to a computer running motor behavioural monitor software which automatically records the number of beam crosses (total locomotor activity). Experiments were carried out under dim light.
On the day of experiment, the animals were administered either drug or vehicle. After treatment, rats were individually placed in the centre of the OF and were left to move freely for 15 min. Before placing each individual rat in the OF, the OF floor was covered with a thin layer of fresh gravel. After behavioural monitoring, the gravel was removed and the floor was cleaned with an alcohol/water solution and left to dry before testing the next rat. All animals were naive to the OF. Two different periods were distinguished and computed, a first 5-min period corresponding to the exploratory phase of the unfamiliar OF and a further 10-min period corresponding to the habituation phase (see Figure 1 ). We measured the overall locomotor activity and other behavioural signs such as rearings, head weavings and head shakes. Head weavings were defined as a lateral side-to-side movement of the head with no net locomotion (Spanos and Yamamoto, 1989) . Likewise, we scored the number of ataxia signs, including behaviours such as occasional fallings during horizontal displacement or by loss of balance while rearing. We also scored the intensity of the disorganization of locomotor activity (e.g. movements not guided by normal exploratory behaviour) using a 0-3 point scale (0=absent, 1=unclear-slight, 2=clearly present, 3=intense) (Tricklebank et al., 1984) . Behaviour was scored during the actual experiments by an experimenter blind to the treatment. Experiments were videotaped for further confirmation of initial visual scores. Rats were used only once and experimental groups were balanced to keep constant the four treatments in the same number of rats in each experimental session. Ratings were carried out simultaneously by two experimenters.
PFC lesions
Electrolytic lesions in the mPFC were performed as follows. Rats were anaesthetized with a mixture of ketamine (90 mg/kg i.p.) and xylazine (5 mg/kg i.p.) and positioned in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA, USA). A bipolar nichrome electrode (120 mm diameter, insulated except at the tip) was stereotaxically descended at two different AP coordinates (AP +3.2 and +3.7 mm), L ¡0.8 (bilateral). Descents were made at x3, x4 and x5.4 mm (DV). Constant current (1 mA, 10 s) was injected at these sites, using a Grass S4 stimulator connected to a Grass constant current stimulus isolation unit. In total, 12 lesion points were made for each rat (six per hemisphere). Coordinates were taken from bregma and duramater (Paxinos and Watson, 2005) . Sham rats underwent the same surgical procedure but electrode descents were not performed to avoid physical damage of the mPFC. After recovering from anaesthesia, rats were returned to their home cages and behavioural experiments were conducted 7 d after the lesion.
To further examine the involvement of PFC on the locomotor effect of MK-801, a group of rats was subjected to cortical transection, as described in Díaz-Mataix et al. (2005) with some modifications. Briefly, rats were deeply anaesthetized with ketamine (90 mg/kg i.p.) and xylazine (5 mg/kg i.p.) and placed in a stereotaxic apparatus. Cortical transection was stereotaxically performed using a fine metal needle (0.6 mm diameter), which was positioned at AP +3.2, DV x6.0, L+0.4 and moved stereotaxically to L ¡4.5. To avoid damaging the sinus and cutting prefrontal afferents to midbrain, transection of right hemisphere was conducted at AP +3.2, DV x6.2, L from x0.4 to x4.5 with an angle of 20x. Figure 2 (a-d) shows the schematic location of PFC lesions and examples of the actual lesions. Rats with incomplete lesions or when these fell outside the medial aspect of the PFC were not included in the study.
Histology
After the completion of behavioural testing, rats were deeply anaesthetized with sodium pentobarbital and were perfused transcardiacally with physiological saline, followed by 4 % paraformaldehyde. Brains were removed from the skull and fixed by immersion in 4 % paraformaldehyde overnight at 4 xC. Tissues were washed and stored in 15-30 % sucrose in PBS at 4 xC, and stored at x70 xC before being sectioned in the coronal or sagittal plane at 50 mm thickness with a cryostat. Sections were mounted and stained with haematoxylin-eosin for histological examination. Verification of prefrontal electrolytic lesion or cortical transection was done using the atlas of Paxinos and Watson (2005) using a Nikon E800 microscope. Digital images were captured using a Nikon Coolpix E995 camera attached to a stereoscopic zoom microscope (Nikon SMZ800) equipped with a plan 1r lens.
Data analysis
Data are given as mean¡standard error of the mean (S.E.M.) and were analysed by one-or two-way analysis of variance (ANOVA) for independent or repeated measures followed by post-hoc Newman-Keuls multiple comparison test. Statistical significance was set at p<0.05.
Results
Characterization of MK-801-induced behaviours
The i.p. administration of 0.1 and 0.2 mg/kg MK-801 induced a dose-dependent and significant increase of locomotor activity. Two-way repeated-measures ANOVA revealed a significant effect of group (F 2,20 =21.1, p<0.00001), time (F 2,40 =31.3, p< 0.000001) and time group interaction (F 4,40 =6.1, p<0.001) (Figure 3a) . Post-hoc analysis revealed significant differences between saline and 0.2 mg/kg MK-801, and between both MK-801 doses. The dose of 0.1 mg/kg MK-801 was not significantly different from saline. However, both doses of MK-801 induced a marked reduction of the number of rearings (to 40 % of basal values) during the exploratory phase (first 5 min) (Figure 3b ). One-way ANOVA showed a significant effect of the dose on rearings (F 2,30 =16.4, p<0.0001). Post-hoc analysis revealed significant differences between both groups of MK-801-treated rats and control rats, with no differences between the MK-801 doses ( Figure 3b) . Table 1 shows the pattern of motor activity (disorganized movements and ataxia signs) and stereotypies induced by MK-801. One-way ANOVA showed that MK-801 induced a dose-dependent and significant effect, increasing locomotor activity and disorganized movements (F 2,30 =12.8, p<0.0001) and the number of fallings during movement (F 2,30 =5.32, p<0.01) in the overall observation period (15 min). The number of head shakes (F 2,30 =0.36, p<0.05) and head weavings (F 2,30 =3.11, p<0.06) was not significantly affected. Figure 2 shows a schematic representation of the location of PFC lesions and the actual PFC damage induced by the electrolytic lesions (coronal sections) and by the cortical transection (sagittal section). On the basis of the above experiments, we choose the dose of 0.2 mg/kg to examine the involvement of the mPFC on the behavioural actions of MK-801. MK-801 effects are given for the total examination period (0-15 min) because the effect on locomotor activity is similar in the exploratory (0-5 min) and habituation phases (5-15 min).
Effect of PFC lesions on MK-801-induced behaviour
To analyse the effect of the PFC electrolytic lesion on the behavioural syndrome induced by MK-801 we performed a two-way ANOVA of the data corresponding to sham and lesioned rats treated with vehicle and MK-801. For locomotor activity, two-way ANOVA revealed a significant effect of the treatment (F 1,26 =104.1, p<0.0001), a trend for the lesion (F 1,26 = 3.28, p=0.08) and a non-significant treatmentrlesion interaction (F 1,26 =1.95, p=0.17). Post-hoc analysis revealed significant differences between vehicle and MK-801 groups (Figure 4a ). MK-801 induced a significant increase in locomotor activity, which was different from that of vehicle in both sham (p<0.0001) and lesioned rats (p<0.0001). Consistent with the marginal, yet non-significant effect of the lesion, there was a slight reduction (p<0.05) of locomotor activity in lesioned animals compared with sham animals (2211¡292 vs. 2804¡160 beam crosses in 15 min, respectively ; Figure 4a ). We also examined the effect of MK-801 on rearings during the initial 5 min, as performed in naive animals (see above) as well as the impact of the mPFC lesion. Two-way ANOVA revealed a significant effect of treatment (F 1,26 =30.7, p<0.0001) a trend for the lesion (F 1,26 =4.5, p=0.06) and non-significant effect of the treatmentrlesion interaction (F 1,26 =2.88, p=0.10) . Post-hoc test revealed a significant difference between vehicle-and MK-801-treated rats in both sham (p<0.0001) and lesioned groups (p<0.05) as well as a significant difference between the vehicle group in sham and lesioned groups (p<0.05) (Figure 4b) .
We calculated the reduction in locomotor activity between 0-5 and 10-15 min (expressed as individual percentages) as a measure of the animal's adaptation to the novel environment. Figure 4c shows the fall in locomotor activity in control rats together with the relative stability of locomotor activity in MK-801-treated rats in both sham-operated and lesioned rats. Two-way ANOVA revealed a significant effect of treatment (F 1,26 =81.4, p<0.00001) a trend for the lesion (F 1,26 =0.07, n.s.) and a non-significant interaction between both factors (F 1,26 =1.2, n.s.).
We subsequently performed cortical transections to produce a greater degree of prefrontal lesion in order to examine the possible dependence of MK-801 effects on PFC activity. For locomotor activity, two-way ANOVA showed a significant effect of treatment (F 1,23 =104.35, p<0.00001) together with a nonsignificant effect of lesion (F 1,23 =0.25, n.s.) but not the interaction between both factors (F 1,23 =0.05, n.s.). Post-hoc test revealed that MK-801 induced a significant increase in the locomotor activity compared with the control group (p<0.0001) (Figure 5a ), whereas a significant decrease in rearing behaviour was observed with MK-801 (p<0.01) (Figure 5b ).
Clz antagonism of MK-801 effect : influence of the mPFC electrolytic lesion Figure 6 shows the total locomotor activity (0-15 min) in sham and lesioned rats treated with vehicle, 0.2 mg/kg MK-801 and 1 mg/kg Clz+0.2 mg/kg MK-801. In addition to examining the overall effect of Clz on MK-801 effects, in this experiment we also tested whether the effect of Clz was dependent on mPFC integrity. The rationale to perform these experiments is based on recent data showing that Clz reversed the hyperactivity of PFC neurons induced by the NMDA receptor antagonist MK-801 (Homayoun and Moghaddam, 2007b ; Kargieman et al., 2007) . We ). * Denotes statistical differences between saline and MK-801 in both experimental groups (sham and lesioned) ; # denotes significant differences between vehicle+MK-801 group of sham vs. lesioned animals (*** p<0.001, *, # p<0.05 ; n=6-8 animals per group). All panels : %, control group ; &, 0.2 mg/kg MK-801. therefore explored the possibility of a PFC-mediated action of Clz to reverse MK-801-induced hyperactivity. A dose of 1 mg/kg Clz was selected because it was found to blockade the behavioural syndrome produced by MK-801 without affecting per se the animal's behaviour (data not shown).
To examine the dependence of Clz reversal of the MK-801-induced effect on PFC integrity we performed two-way ANOVA of the data of sham and lesioned animals treated with MK-801 alone or in combination with Clz. Two-way ANOVA of all experimental groups (vehicle, MK-801 alone, Clz+MK-801, both sham and lesioned) revealed a significant effect of treatment (F 2,40 =46.7, p<0.0001) a marginally significant effect of lesion (F 1,40 =3.66, p=0.06) and a nonsignificant treatmentrlesion interaction (F 2,40 =0.93, p=0.39). Post-hoc tests revealed significant differences between MK-801 and vehicle in sham and lesioned rats, between MK-801 alone and Clz+MK-801 in sham and lesioned rats, and between the MK-801 group in sham and lesioned rats (Figure 6a ). Clz (1 mg/kg) was effective in blockading the hyperactivity induced by MK-801 without any effect per se on the basal locomotor activity (data not shown). Moreover, we observed that Clz failed to blockade the decrease in rearing behaviour induced by MK-801 in both sham and lesioned animals (Figure 6b) . Table 2 shows the antagonizing effect of Clz on MK-801-induced signs of uncoordinated motor activity, ataxia signs and stereotypies in sham and PFC-lesioned rats. Two-way ANOVA of the data revealed (1) a significant effect of treatment (F 2,40 =10.46, p<0.0002), a non-significant effect of lesion or treatmentrlesion interaction for head weavings ; (2) a significant effect of treatment (F 2,40 =39.66, p<0.0001) and lesion (F 1,40 =7.37, p<0.01) but not of the interaction for disorganized movement ; (3) a significant effect of treatment (F 2,40 =8.46, p<0.001) and a non-significant of lesion or interaction for the number of falls, and (4) a trend for treatment (F 2,40 =2.63, p=0.08), non-significant effect for lesion (F 1,40 =1.37, p<0.25) and significant effect of treatmentrlesion interaction (F 2,40 =4.67, p<0.05) for the head shakes. Post-hoc analysis revealed that MK-801 produced an overall increase in these behaviours that was reversed by Clz in both groups of animals.
Discussion
The present study further characterized the motor behavioural syndrome induced by MK-801 in rats and specifically examined whether these effects depend on the cellular integrity of the PFC. Moreover, we examined whether the ability of the atypical antipsychotic Clz to reverse MK-801-induced behavioural signs depends also on PFC integrity. Rearings pre-treatment were markedly affected by an electrolytic lesion, which produced only a slight (21 %) attenuation of the locomotor activity induced by MK-801 whereas cortical transection did not affect it. Overall, this suggests that the motor syndrome induced by MK-801 and its antagonism by Clz is mainly driven by blockade of NMDA receptors outside the PFC.
Characterization of MK-801-induced behaviour
The main effects induced by MK-801 are in agreement with previous literature (Andine et al., 1999 ; Deustch et al., 1997 ; Geyer and Ellenbroek, 2003 ; Leriche et al., 2003 ; Wu et al., 2005) . MK-801 induced a behavioural syndrome characterized by hyperlocomotion with disorganized movements (e.g. not guided by normal exploration), slight ataxia signs, stereotypical behaviours, such as head weavings, and a marked suppression of rearings. Although hyperlocomotion has been extensively examined by previous reports, the effect of NMDA receptor blockade on rearings and other behaviours has received comparatively little attention (Ö gren et al., 1994 (Ö gren et al., , Wu et al., 2005 .
Rearings are a component of the natural exploratory behaviour directly related to the environment novelty (Bardo et al., 1990 ; Fink and Smith, 1980 ; Geyer et al., 1986) . Thus, untreated rats placed in the unfamiliar OF showed a greater score than MK-801-treated rats in rearing behaviour during the first 5 min, corresponding to the exploratory phase. This reduction in rearings was associated with an increase in horizontal locomotor activity. The lower dose of MK-801 (0.1 mg/kg), which did not evoke hyperlocomotion evoked a similar reduction in rearings, suggesting two independent effects of MK-801. Actually, MK-801 reduced regains to the same extent in habituated and non-habituated animals (M. C. Scorza, unpublished observations), which indicates that MK-801 alters the adaptation to novel environments independently of previous experience. The opposite effects of MK-801 on rearings and locomotor activity are discordant with those of amphetamine, which concurrently increases motor activity and rearings (Kelly et al., 1975 ; Mele et al., 1998 ; Pešic et al., 2003 ; M. C. Scorza, unpublished observations) . This further suggests that rearing suppression by MK-801 is not secondary to increased locomotor activity. Further, ataxia induced by NMDA receptor blockade does not seem to be involved in the suppression of rearings since, as seen with MK-801, phencyclidine (5 mg/kg i.p.) increased locomotor activity and decreased rearings but did not induce ataxia (M. C. Scorza et al., unpublished observations) .
Interestingly, both the selective electrolytic lesion of the mPFC and the more widespread lesion induced by cortical transection reduced rearings without affecting basal locomotor activity. Rearing behaviour has been generally associated with subcortical dopamine activation (Bardo et al., 1990 ; Clarke et al., 1988 ; Fink and Smith, 1980) . Our results indicate that glutamatergic transmission in the PFC is also very important for the expression of this behaviour. Indeed, dopaminergic and GABAergic neurons of the mesolimbic system are innervated and controlled, directly or indirectly, by descending glutamatergic afferents from the mPFC Carr and Sesack, 2000 ; Díaz-Mataix et al., 2005 ; Sesack and Pickel, 1992 ; Taber and Fibiger, 1995) . Cortical transection, as performed herein, fully suppressed burst activity in dopaminergic neurons of the ventral tegmental area . Thus, it is possible that removal of excitatory inputs from the PFC prevents the rise in dopaminergic activity that assigns salience to novel environmental stimuli (Schultz, 1997) , thus, decreasing this component of exploratory behaviour.
Ataxia and motor uncoordination induced by MK-801 may perhaps be accounted for the blockade of certain NMDA receptor subunits (NMDAR 2C and/ or NMDAR 2D , which are expressed in granule cells in the cerebellum (Pizzi et al., 1999) 
and bind [
3 H]MK-801 (Nakanishi, 1992) . Indeed, the alteration of GABAergic transmission in this structure evokes ataxia signs in mice (Chiu et al., 2005) .
MK-801 caused increased head weavings without altering head shakes. The latter is natural behaviour that can be enhanced by the administration of serotonergic agents targeting 5-HT 2 receptors (Glennon and Lucki, 1989) . However, lateral head weaving is a pharmacologically induced stereotypy which is present, for instance, in the serotonergic syndrome induced by 5-HT 1A agonists (Tricklebank et al., 1984) . In this regard, previous studies have shown that the stereotypic behaviour induced by MK-801 can be blockaded by selective 5-HT 1A receptor antagonists (Lö scher and Hö nack, 1993) , an effect perhaps accounted for by the serotonin increase observed in microdialysis studies (Ló pez-Gil et al., 2007) .
Effect of PFC lesions on MK-801-induced behaviour
Phencyclidine and MK-801 produce a marked disruption of the neuronal activity in the mPFC, with an overall increase in discharge rate, although some neuronal populations are inhibited (Homayoun and Moghaddam, 2007b ; Jackson et al., 2004 ; Kargieman et al., 2007 ; Suzuki et al., 2002) . The increased pyramidal neuron activity in the PFC may involve NDMA receptor blockade on local (Homayoun and Moghaddam, 2007b) or distal elements projecting to the PFC (Kargieman et al., 2007) . Thus, blockade of NMDA receptor-mediated tonic glutamatergic inputs onto local GABAergic interneurons and/or GABAcontrolled excitatory afferents to the PFC would result in pyramidal cell disinhibition (Krystal et al., 2003 ; Tsai and Coyle, 2002) . In support of the latter possibility is the fact that local blockade of NMDA receptors did not increase neuronal activity in the mPFC, yet blockade in the CA1/subiculum, an afferent area to the mPFC, increased the activity of mPFC neurons ( Jodo et al., 2005 ; Suzuki et al., 2002) . Moreover, unlike systemic administration, the local application of ketamine and phencyclidine did not increase serotonin release in the mPFC (Amargó s-Bosch et al., 2006) . Similarly, systemic administration, but not local application in the mPFC of MK-801 increased serotonin and glutamate output in the mPFC (Ló pez-Gil et al., 2007) . However, systemic MK-801 administration reduced firing rate of fast-spiking interneurons in the mPFC (Homayoun and Moghaddam, 2007b) .
The main working hypothesis of the present study is that the increased PFC activity (secondary to the effect of MK-801 in other brain areas) may drive, via descending excitatory afferents, an increase in the activity of cortical and subcortical motor areas which would result in the MK-801-induced hyperlocomotion. Overall, the PFC has been implicated in cognitive change (Verma and Moghaddam, 1996) and the regulation of the sensoriomotor gating deficit (Schwabe and Koch, 2004) induced by NMDA receptor antagonists. This is in agreement with the role of PFC in higher brain functions, such as working memory, action planning and behavioural inhibition (Fuster, 1997 ; Goldman-Rakic, 1996 ; Miller and Cohen, 2001) . However, other studies suggest the participation of the PFC in the hyperactivity and stereotypies induced by NMDA antagonist (Feenstra et al., 2002 ; Jentsch et al., 1998 ; Takahata and Moghaddam, 2003) . The present data do not support this view completely. On the contrary, it appears that the behavioural syndrome induced by MK-801 is mainly independent of PFC inputs onto motor areas, either cortical or subcortical.
One way to reconcile the present observations with the effects of NMDA receptor antagonists in rat and human PFC Jackson et al., 2004 ; Kargieman et al., 2007 ; Suzuki et al., 2002) is that NMDA receptor blockade in a distal brain area may result in a concurrent subsequent alteration of glutamatergic neurotransmission in the PFC -which would account for the cognitive and perceptual changesand in other structures involved in motor behaviour. The hippocampus has been proposed to mediate the increase in PFC neuronal activity via an activation of hippocampus-prefrontal inputs (Jodo et al., 2005) . The hippocampus also projects, among other structures, to the ventral striatum and may modulate information flow through basal ganglia circuits (Grace, 2000) .
However, NMDA receptor blockade in other brain structures may also account. Hence, MK-801 enhances c-fos expression in various thalamic nuclei that project to motor and association areas, including the striatum and PFC (Vaisanen et al., 2004) . Recent studies using double in-situ hybridization show that phencyclidine enhances c-fos in glutamatergic neurons of various thalamic nuclei, including the mediodorsal and centromedial nuclei, which project densely to the PFC, but not in GABAergic neurons of the reticular nucleus of the thalamus, which inhibits the rest of thalamic nuclei (Kargieman et al., 2007) . Thus, NMDA receptor antagonists might inhibit tonic NMDA inputs onto GABAergic neurons of the reticular nucleus, an effect that would then disinhibit several thalamic projections to association and motor areas, resulting in the array of different pharmacological effects produced by these agents.
Clz antagonism of MK-801 effect : the effect of the mPFC lesion
The behavioural syndrome produced by NMDA antagonists has been widely used as an animal model to study the mechanism of action of conventional and atypical antipsychotics (Geyer and Ellenbroek, 2003) . Classical neuroleptics modulate excitatory inputs onto limbic striatum following the blockade of dopamine D 2 receptors. However, several studies indicate that atypical antipsychotics have prominent actions in the PFC. First, Clz displays lower affinity for D 2 than for 5-HT 2A receptors (Meltzer, 1999) which are expressed by a very large proportion of PFC neurons (Amargó s- Bosch et al., 2004 ; Santana et al., 2004) . Second, 5-HT 2A receptor antagonism contributes substantially to the ability of atypical antipsychotics to attenuate this behavioural effect of NMDA antagonists (Gleason and Shannon, 1997) . Third, Clz acts on PFC 5-HT 1A receptors to modulate the local dopamine release, an effect potentially involved in the procognitive actions of Clz, by a local action . Finally, Clz reverses the increase in glutamatergic transmission in the PFC, as assessed in neurochemical and electrophysiological studies (Homayoun and Moghaddam, 2007b ; Kargieman et al., 2007 ; Ló pez-Gil et al., 2007) . Overall, these results suggest that the reversal by Clz of the motor syndrome induced by MK-801 might require the anatomical and functional integrity of the PFC. However, contrary to these expectations, the present data indicate that Clz antagonized the MK-801-induced hyperlocomotion equally in sham and lesioned rats.
Since the behavioural repertoire induced by MK-801 and the antagonism by Clz seems to be mostly mediated by pathways involving motor structures, it seems reasonable to assume that Clz may act at once in various brain structures. Thus, in addition to serotonin receptors in the mPFC, it may target such receptors in other cortical or subcortical areas, which also show a high abundance of 5-HT 1A and 5-HT 2A/2C receptors (Pompeiano et al. 1992 (Pompeiano et al. , 1994 . At the dose used, Clz occupies a minor proportion of dopamine D 2 receptors (y10 %, Schotte et al., 1993) , which suggests that dopaminergic blockade is not involved in the antagonism of MK-801-induced hyperlocomotion. An alternative mechanism is the blockade of a 1 -adrenoceptors, for which Clz shows high in-vitro affinity (Arnt and Skarsfeldt, 1998 ; Bymaster et al., 1996) . In this regard, it was found that prazozin, an a 1 -adrenoceptor antagonist reduces MK-801-induced hyperlocomotion and stereotypies (Harkin et al., 2001) . Interestingly, the decrease in rearings elicited by MK-801 was not antagonized by Clz, indicating once again that the NMDA receptors involved in the regulation of locomotor and rearing behaviour act via different pathways. Indeed, the present results support the view that the PFC plays a minor role in hyperlocomotion evoked by MK-801, but they do not exclude at all the involvement of this cortical area in the cognitive changes evoked by NMDA receptor blockade, which occurs at MK-801 doses lower than those increasing locomotor activity (Jackson et al., 2004) .
Further work is needed to clarify what specific brain regions are involved in the behavioural syndrome induced by NMDA receptor antagonists and the mechanism of action of atypical antipsychotics to reverse these effects.
